Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
5.22
Nov 06 • 3:59 PM ET Dollar change+0.21 Percentage change(4.19%)
Aftermarket Close
5.14
Aftermarket • 6:40 PM ET Dollar change-0.08 Percentage change(-1.53%)
Index
-
Market Cap
78.21M
Enterprise Value
78.73M
Income
-10.92M
Sales
31.27M
Book/sh
1.16
Cash/sh
0.26
Employees
93
IPO
Aug 11, 2009
P/E
-
Forward P/E
-
PEG
-
P/S
2.50
P/B
4.49
P/C
20.26
P/FCF
115.01
EV/EBITDA
-
EV/Sales
2.52
Quick Ratio
0.96
Current Ratio
0.96
Debt/Eq
0.27
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
-0.73
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
20.68% 2.82%
Sales past 3/5Y
1.95% 3.52%
EPS Y/Y TTM
-244.92%
Sales Y/Y TTM
-25.68%
EPS Q/Q
-476.57%
Sales Q/Q
-98.46%
Insider Own
41.60%
Insider Trans
0.00%
Inst Own
20.88%
Inst Trans
-6.64%
ROA
-14.91%
ROE
-42.92%
ROIC
-50.43%
Gross Margin
86.22%
Oper. Margin
-29.58%
Profit Margin
-34.92%
SMA20
-14.84%
SMA50
-22.68%
SMA200
8.08%
Trades
Shs Outstand
14.98M
Shs Float
8.75M
52W High
9.28 -43.75%
52W Low
1.43 263.87%
Volatility
13.40% 14.85%
ATR (14)
0.74
RSI (14)
43.04
Beta
0.28
Rel Volume
0.94
Avg Volume
89.48K
Volume
84,383
Perf Week
11.30%
Perf Month
-25.21%
Perf Quarter
-32.99%
Perf Half Y
43.84%
Perf YTD
69.14%
Perf Year
207.38%
Perf 3Y
241.70%
Perf 5Y
151.18%
Perf 10Y
35.44%
Prev Close
5.01
Price
5.22
Change %
4.19%
Consensus
Strong Buy
Avg. Price Target
$9.75
Implied Upside
+86.8%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 12, 2012Reiterated
UBS logoUUBS
Neutral$6.50 → $5-4.2%
Feb 01, 2011Reiterated
UBS logoUUBS
Neutral$8 → $6.50+24.5%
Dec 16, 2010Downgrade
UBS logoUUBS
Buy → Neutral$10 → $8+53.3%
Aug 17, 2010Reiterated
UBS logoUUBS
Buy$11 → $10+91.6%
Aug 17, 2010Reiterated
MMorgan Joseph
Buy$15 → $10+91.6%
Aug 17, 2010Downgrade
JEF logoJJefferies
Buy → Hold$13 → $5.50+5.4%
May 14, 2010Reiterated
MMorgan Joseph
Buy$21 → $15+187.4%
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.
FounderMr. A. J. Kazimi MBA
Vice President Accounting & Finance and CFOMr. John Michael Hamm C.M.A.
Vice President of Organizational DevelopmentMr. Todd M. Anthony
Managing Director of Banking & Investor RelationsMr. Adam S. Mostafa